| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.069 | 0.02 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.02 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.02 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.02 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.02 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.071 | 0.03 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.07 | 0.03 |